UK Group Says HIV Drug-Selection Software Offers Improvement over Rules-Based Approach | GenomeWeb

By Uduak Grace Thomas

This article has been updated from a version posted Oct 22 to reflect an amendment to the title.

A UK-based non-profit has launched an experimental modeling system that accurately predicts how patients with HIV and AIDS will respond to antiretroviral drug combinations 80 percent of the time — a 20 percent improvement over the rules-based interpretation system commonly used by physicians, according to its developers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.